Focus Partners Advisor Solutions’s INmune Bio INMB Stock Holding History

Focus Partners Advisor Solutions’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$48.6K	Buy	43,025 +1,928	+5%	+$2.75K	﹤0.01%	1219
2025 Q4	$64.1K	Buy	41,097 +147	+0.4%	+$262	﹤0.01%	1065
2025 Q3	$84.8K	Sell	40,950 -7,863	-16%	-$18K	﹤0.01%	1100
2025 Q2	$113K	Buy	48,813 +37,224	+321%	+$273K	﹤0.01%	1050
2025 Q1	$90.5K	Buy	+11,589	New	+$92K	﹤0.01%	942

Other funds holding INMB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Focus Partners Advisor Solutions's INMB Position: Q1 2026 in Review

Focus Partners Advisor Solutions increased its INmune Bio (INMB) stake by 4.7% in Q1 2026, buying an estimated $2.75K and bringing the position to 43,025 shares worth $48.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1219.

Focus Partners Advisor Solutions first reported a position in INMB in Q1 2025 and has held it in 5 quarters since. The position peaked at $113K in Q2 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

Focus Partners Advisor Solutions held 43,025 shares of INmune Bio worth $48.6K as of Q1 2026.
Focus Partners Advisor Solutions bought 1,928 INmune Bio shares in Q1 2026, an estimated $2.75K.
INmune Bio made up ﹤0.01% of Focus Partners Advisor Solutions's portfolio in Q1 2026, its #1219 holding.
Focus Partners Advisor Solutions first reported a position in INmune Bio in Q1 2025 and has held it in 5 quarters since.
Focus Partners Advisor Solutions's INmune Bio position peaked at $113K in Q2 2025.
82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q1 2026, filed 13 May 2026.